Federal fraudbusters focus on drug pricing while quest for Rx discount card continuesNovember 1st 2001
With the government spending billions to fight terrorism at home and abroad, federal investigators are looking closely at all health care programs for opportunities to stymie abuses and collect big penalties.
Hepatitis B: An ssessment of current and future treatment options (PDF)October 1st 2001
Interferon alfa-2b and the nucleoside analog lamivudine are the currently available options for treating chronic hepatitis B virus (HBV) infection. This article reviews major efficacy findings with these agents, defines their role according to patients' clinical status, and provides the latest data on optimal duration of therapy, predictors of response, and long-term effects. The authors also explore the emergence of hepatitis B immune globulin for post-liver transplant HBV prophylaxis and offer a progress report on experimental therapies for chronic HBV infection.
Dalteparin for enoxaparin interchange: Chart review shows promising clinical, economic outcomesOctober 1st 2001
University Hospital and Medical Center (Tamarac)/University of Florida (Gainesville)-Dalteparin appears to be at least as clinically effective as enoxaparin for the prevention or treatment of the consequences of venous and arterial thromboembolic diseases, say clinicians from these two facilities.
Market share shift analysis identifies scenario allowing maximum number of ED patients to be treatedSeptember 1st 2001
Minneapolis Veterans Administration Medical Center-Decreasing or eliminating the use of alprostadil-based erectile dysfunction treatments and converting to 100% sildenafil use would save this VA medical center more than $101,000 annually. Furthermore, the projected savings would allow an additional 405 men with erectile dysfunction to be treated for an entire year, say clinicians at this facility.
Metformin prevents diabetes in high-risk subjects, but effect is trumped by lifestyle changesSeptember 1st 2001
For the first time, a large clinical trial has shown that a medication can help prevent type 2 diabetes in high-risk individuals. At the same time, drug therapy emerged as a less effective preventive strategy than fairly modest diet and exercise changes.
Florida-Pfizer deal charts new territory in overall cost control, but can it work?September 1st 2001
The unprecedented Medicaid disease management deal struck between Florida and Pfizer this summer represents an important "move past unit cost control into total disease control," according to Perry Cohen, PharmD.
Political climate could shed new light on Medicare pharmacy benefit, related issuesSeptember 1st 2001
A few weeks ago, it looked like the national economic slowdown, which was eroding the anticipated federal budget surplus, might put the costly Medicare pharmaceutical benefit on the endangered list. Congress was having trouble agreeing on a coverage plan, and interest groups were squabbling over how to craft a fair and effective pharmacy program for the elderly.
Fees and formularies move to center of Medicare Rx benefit debateAugust 1st 2001
Flush from victory in passing patients' rights legislation, Senate Democrats are expected to push for a Medicare prescription drug benefit this fall. The new Senate leadership seems to have found that championing health care is a winning strategy and is eager to build on its success.